Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2015
Publication Date Jun 2015
Product Type Report
Pages 206
Single User License help $ 2000.00
Site User License help $ 4000.00
Corporate User License help $ 6000.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2015’, provides an overview of the H5N1 Infection (Avian Influenza)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for H5N1 Infection (Avian Influenza)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding H5N1 Infection (Avian Influenza) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Akshaya Bio Inc. AlphaVax, Inc. Antigen Express, Inc. Aphios Corporation Aprogen, Inc. BioDiem Ltd CEL-SCI Corporation Cocrystal Pharma, Inc. Daiichi Sankyo Company, Limited Emergent BioSolutions Inc. Gemmus Pharma Inc. GlaxoSmithKline Plc Green Cross Corporation Hemispherx Biopharma, Inc. iBio, Inc. Immunovaccine, Inc. Inovio Pharmaceuticals, Inc. Johnson & Johnson Kineta, Inc. Medicago Inc. Medigen Biotechnology Corporation Microgen Scientific Industrial Company for Immunobiological Medicines Myelo Therapeutics GmbH NanoBio Corporation Nanotherapeutics, Inc. NanoViricides, Inc. NewLink Genetics Corporation Novartis AG OPKO Health, Inc. PaxVax PDS Biotechnology Corporation PeptiDream Inc. Protein Sciences Corporation REPLICor Inc. SIGA Technologies, Inc. Sirnaomics, Inc. Takeda Pharmaceutical Company Limited TechnoVax, Inc. Vaxart, Inc. Vaxin, Inc. Vaxine Pty Ltd VaxInnate Corporation

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
H5N1 Infection (Avian Influenza) Overview 10
Therapeutics Development 11
Pipeline Products for H5N1 Infection (Avian Influenza) - Overview 11
Pipeline Products for H5N1 Infection (Avian Influenza) - Comparative Analysis 12
H5N1 Infection (Avian Influenza) - Therapeutics under Development by Companies 13
H5N1 Infection (Avian Influenza) - Therapeutics under Investigation by Universities/Institutes 18
H5N1 Infection (Avian Influenza) - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
H5N1 Infection (Avian Influenza) - Products under Development by Companies 22
H5N1 Infection (Avian Influenza) - Products under Investigation by Universities/Institutes 27
H5N1 Infection (Avian Influenza) - Companies Involved in Therapeutics Development 28
Akshaya Bio Inc. 28
AlphaVax, Inc. 29
Antigen Express, Inc. 30
Aphios Corporation 31
Aprogen, Inc. 32
BioDiem Ltd 33
CEL-SCI Corporation 34
Cocrystal Pharma, Inc. 35
Daiichi Sankyo Company, Limited 36
Emergent BioSolutions Inc. 37
Gemmus Pharma Inc. 38
GlaxoSmithKline Plc 39
Green Cross Corporation 40
Hemispherx Biopharma, Inc. 41
iBio, Inc. 42
Immunovaccine, Inc. 43
Inovio Pharmaceuticals, Inc. 44
Johnson & Johnson 45
Kineta, Inc. 46
Medicago Inc. 47
Medigen Biotechnology Corporation 48
Microgen Scientific Industrial Company for Immunobiological Medicines 49
Myelo Therapeutics GmbH 50
NanoBio Corporation 51
Nanotherapeutics, Inc. 52
NanoViricides, Inc. 53
NewLink Genetics Corporation 54
Novartis AG 55
OPKO Health, Inc. 56
PaxVax 57
PDS Biotechnology Corporation 58
PeptiDream Inc. 59
Protein Sciences Corporation 60
REPLICor Inc. 61
SIGA Technologies, Inc. 62
Sirnaomics, Inc. 63
Takeda Pharmaceutical Company Limited 64
TechnoVax, Inc. 65
Vaxart, Inc. 66
Vaxin, Inc. 67
Vaxine Pty Ltd 68
VaxInnate Corporation 69
H5N1 Infection (Avian Influenza) - Therapeutics Assessment 70
Assessment by Monotherapy Products 70
Assessment by Combination Products 71
Assessment by Target 72
Assessment by Mechanism of Action 74
Assessment by Route of Administration 76
Assessment by Molecule Type 78
Drug Profiles 80
A-06 - Drug Profile 80
AE-443p - Drug Profile 81
Alferon LDO - Drug Profile 83
APP-0205 - Drug Profile 85
APP-309 - Drug Profile 86
AT-301 - Drug Profile 87
CEL-1000 - Drug Profile 88
DP-C005 - Drug Profile 90
FBF-001 - Drug Profile 91
FDX-000 - Drug Profile 92
Gamma-Flu - Drug Profile 93
GP-1001 - Drug Profile 94
GP-1002 - Drug Profile 95
GP-1681 - Drug Profile 96
GREFLU/VIE - Drug Profile 98
HAI-05 - Drug Profile 99
iHA-24 - Drug Profile 100
Influ-nRNA - Drug Profile 101
influenza (strain H5N1, H1N1) vaccine - Drug Profile 102
influenza [strain A/H5N1] vaccine - Drug Profile 103
influenza [strain H5N1, H1N1] vaccine - Drug Profile 104
influenza [strain H5N1, H7N2, H9N2] virus like particle vaccine - Drug Profile 105
influenza [strain H5N1] (split virion) vaccine - Drug Profile 106
influenza [strain H5N1] vaccine - Drug Profile 107
influenza [strain H5N1] vaccine - Drug Profile 108
influenza [strain H5N1] vaccine - Drug Profile 109
influenza [strain H5N1] vaccine - Drug Profile 110
influenza [strain H5N1] vaccine - Drug Profile 111
influenza [strain H5N1] vaccine - Drug Profile 113
influenza [strain H5N1] vaccine - Drug Profile 114
influenza [strain H5N1] vaccine - Drug Profile 115
influenza [strain H5N1] vaccine - Drug Profile 116
influenza [strain H5N1] virus like particle vaccine + Glucopyranosyl Lipid A Adjuvant - Drug Profile 117
influenza A vaccine - Drug Profile 119
influenza vaccine - Drug Profile 120
influenza vaccine - Drug Profile 121
influenza vaccine - Drug Profile 122
influenza vaccine - Drug Profile 124
influezna [strain H5N1] virus like particles vaccine - Drug Profile 125
Innate Immune Adjuvants - Drug Profile 127
INO-3401 - Drug Profile 128
INO-3510 - Drug Profile 129
INO-3605 - Drug Profile 130
INO-3609 - Drug Profile 131
IPS-07 series - Drug Profile 132
JNJ-872 - Drug Profile 133
KD-295 - Drug Profile 135
KIB-PCI - Drug Profile 136
MG-1109 - Drug Profile 137
Monoclonal Antibody to Inhibit Hemagglutinin for Influenza - Drug Profile 139
MVAH-5HA - Drug Profile 140
Myelo-001 - Drug Profile 141
NVINF-1 - Drug Profile 142
NVINF-2 - Drug Profile 144
OrniFlu - Drug Profile 145
PanBlok - Drug Profile 146
PDS-0102 - Drug Profile 148
PNSIA-28 - Drug Profile 149
PNSIA-49 - Drug Profile 150
PXVX-0103 - Drug Profile 151
REP-9 - Drug Profile 153
rintatolimod - Drug Profile 154
Small Molecule for Influenza Virus - Drug Profile 156
Small Molecules to Activate Sirtuin for Influenza - Drug Profile 157
Small Molecules to Inhibit Endonuclease for Flu - Drug Profile 158
STP-702 - Drug Profile 159
Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile 160
TVX-003 - Drug Profile 161
VAX-161 - Drug Profile 162
VH-244 - Drug Profile 163
H5N1 Infection (Avian Influenza) - Recent Pipeline Updates 165
H5N1 Infection (Avian Influenza) - Dormant Projects 186
H5N1 Infection (Avian Influenza) - Discontinued Products 191
H5N1 Infection (Avian Influenza) - Product Development Milestones 192
Featured News & Press Releases 192
Appendix 200
Methodology 200
Coverage 200
Secondary Research 200
Primary Research 200
Expert Panel Validation 200
Contact Us 200
Disclaimer 201

List of Tables
List of Tables
Number of Products under Development for H5N1 Infection (Avian Influenza), H1 2015 16
Number of Products under Development for H5N1 Infection (Avian Influenza) - Comparative Analysis, H1 2015 17
Number of Products under Development by Companies, H1 2015 19
Number of Products under Development by Companies, H1 2015 (Contd..1) 20
Number of Products under Development by Companies, H1 2015 (Contd..2) 21
Number of Products under Development by Companies, H1 2015 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H1 2015 23
Comparative Analysis by Late Stage Development, H1 2015 24
Comparative Analysis by Clinical Stage Development, H1 2015 25
Comparative Analysis by Early Stage Development, H1 2015 26
Products under Development by Companies, H1 2015 27
Products under Development by Companies, H1 2015 (Contd..1) 28
Products under Development by Companies, H1 2015 (Contd..2) 29
Products under Development by Companies, H1 2015 (Contd..3) 30
Products under Development by Companies, H1 2015 (Contd..4) 31
Products under Investigation by Universities/Institutes, H1 2015 32
H5N1 Infection (Avian Influenza) - Pipeline by Akshaya Bio Inc., H1 2015 33
H5N1 Infection (Avian Influenza) - Pipeline by AlphaVax, Inc., H1 2015 34
H5N1 Infection (Avian Influenza) - Pipeline by Antigen Express, Inc., H1 2015 35
H5N1 Infection (Avian Influenza) - Pipeline by Aphios Corporation, H1 2015 36
H5N1 Infection (Avian Influenza) - Pipeline by Aprogen, Inc., H1 2015 37
H5N1 Infection (Avian Influenza) - Pipeline by BioDiem Ltd, H1 2015 38
H5N1 Infection (Avian Influenza) - Pipeline by CEL-SCI Corporation, H1 2015 39
H5N1 Infection (Avian Influenza) - Pipeline by Cocrystal Pharma, Inc., H1 2015 40
H5N1 Infection (Avian Influenza) - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 41
H5N1 Infection (Avian Influenza) - Pipeline by Emergent BioSolutions Inc., H1 2015 42
H5N1 Infection (Avian Influenza) - Pipeline by Gemmus Pharma Inc., H1 2015 43
H5N1 Infection (Avian Influenza) - Pipeline by GlaxoSmithKline Plc, H1 2015 44
H5N1 Infection (Avian Influenza) - Pipeline by Green Cross Corporation, H1 2015 45
H5N1 Infection (Avian Influenza) - Pipeline by Hemispherx Biopharma, Inc., H1 2015 46
H5N1 Infection (Avian Influenza) - Pipeline by iBio, Inc., H1 2015 47
H5N1 Infection (Avian Influenza) - Pipeline by Immunovaccine, Inc., H1 2015 48
H5N1 Infection (Avian Influenza) - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 49
H5N1 Infection (Avian Influenza) - Pipeline by Johnson & Johnson, H1 2015 50
H5N1 Infection (Avian Influenza) - Pipeline by Kineta, Inc., H1 2015 51
H5N1 Infection (Avian Influenza) - Pipeline by Medicago Inc., H1 2015 52
H5N1 Infection (Avian Influenza) - Pipeline by Medigen Biotechnology Corporation, H1 2015 53
H5N1 Infection (Avian Influenza) - Pipeline by Microgen Scientific Industrial Company for Immunobiological Medicines, H1 2015 54
H5N1 Infection (Avian Influenza) - Pipeline by Myelo Therapeutics GmbH, H1 2015 55
H5N1 Infection (Avian Influenza) - Pipeline by NanoBio Corporation, H1 2015 56
H5N1 Infection (Avian Influenza) - Pipeline by Nanotherapeutics, Inc., H1 2015 57
H5N1 Infection (Avian Influenza) - Pipeline by NanoViricides, Inc., H1 2015 58
H5N1 Infection (Avian Influenza) - Pipeline by NewLink Genetics Corporation, H1 2015 59
H5N1 Infection (Avian Influenza) - Pipeline by Novartis AG, H1 2015 60
H5N1 Infection (Avian Influenza) - Pipeline by OPKO Health, Inc., H1 2015 61
H5N1 Infection (Avian Influenza) - Pipeline by PaxVax, H1 2015 62
H5N1 Infection (Avian Influenza) - Pipeline by PDS Biotechnology Corporation, H1 2015 63
H5N1 Infection (Avian Influenza) - Pipeline by PeptiDream Inc., H1 2015 64
H5N1 Infection (Avian Influenza) - Pipeline by Protein Sciences Corporation, H1 2015 65
H5N1 Infection (Avian Influenza) - Pipeline by REPLICor Inc., H1 2015 66
H5N1 Infection (Avian Influenza) - Pipeline by SIGA Technologies, Inc., H1 2015 67
H5N1 Infection (Avian Influenza) - Pipeline by Sirnaomics, Inc., H1 2015 68
H5N1 Infection (Avian Influenza) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 69
H5N1 Infection (Avian Influenza) - Pipeline by TechnoVax, Inc., H1 2015 70
H5N1 Infection (Avian Influenza) - Pipeline by Vaxart, Inc., H1 2015 71
H5N1 Infection (Avian Influenza) - Pipeline by Vaxin, Inc., H1 2015 72
H5N1 Infection (Avian Influenza) - Pipeline by Vaxine Pty Ltd, H1 2015 73
H5N1 Infection (Avian Influenza) - Pipeline by VaxInnate Corporation, H1 2015 74
Assessment by Monotherapy Products, H1 2015 75
Assessment by Combination Products, H1 2015 76
Number of Products by Stage and Target, H1 2015 78
Number of Products by Stage and Mechanism of Action, H1 2015 80
Number of Products by Stage and Route of Administration, H1 2015 82
Number of Products by Stage and Molecule Type, H1 2015 84
H5N1 Infection (Avian Influenza) Therapeutics - Recent Pipeline Updates, H1 2015 170
H5N1 Infection (Avian Influenza) - Dormant Projects, H1 2015 191
H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..1), H1 2015 192
H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..2), H1 2015 193
H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..3), H1 2015 194
H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..4), H1 2015 195
H5N1 Infection (Avian Influenza) - Discontinued Products, H1 2015 196

List of Figures
List of Figures
Number of Products under Development for H5N1 Infection (Avian Influenza), H1 2015 16
Number of Products under Development for H5N1 Infection (Avian Influenza) - Comparative Analysis, H1 2015 17
Number of Products under Development by Companies, H1 2015 18
Comparative Analysis by Clinical Stage Development, H1 2015 25
Comparative Analysis by Early Stage Products, H1 2015 26
Assessment by Monotherapy Products, H1 2015 75
Number of Products by Top 10 Targets, H1 2015 77
Number of Products by Stage and Top 10 Targets, H1 2015 77
Number of Products by Top 10 Mechanism of Actions, H1 2015 79
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 79
Number of Products by Top 10 Routes of Administration, H1 2015 81
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 81
Number of Products by Top 10 Molecule Types, H1 2015 83
Number of Products by Stage and Top 10 Molecule Types, H1 2015 83

Title Date Price
Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report
By QYResearch
The Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Digital Camera Head for Endoscopes industry. The re ...Read More
Apr 2016 $3600.00
China Pharmaceutical Guidebook Series (4) Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Traditional Chinese Medicines and Natural Medicines
By Access China Management Consulting Ltd
The traditional medicines in Orient, especially, the traditional Chinese medicines are always regarded by occidental as mysterious medicines. Until today not only the chemical composition of tradition ...Read More
May 2015 $750.00
Latest Guide to Chinese Pharmaceutical GMP Regulations
By Access China Management Consulting Ltd
China possesses a fourth population in the world and has one of the largest drug markets round the world. By 2012, sales on the Chinese drug market have reached RMB 926.1billion (about US$147 billion) ...Read More
Jul 2015 $750.00
"Acne vulgaris "- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acne vulgaris  - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the disease and ...Read More
Apr 2016 $4950.00
"Acute coronary syndrome(ACS)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acute coronary syndrome (ACS) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of th ...Read More
Apr 2016 $4950.00
"Acute heart failure(AHF)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acute heart failure (AHF) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the di ...Read More
Apr 2016 $4950.00
"Acute ischemic stroke (AIS)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acute ischemic stroke (AIS) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the ...Read More
Apr 2016 $4950.00
"Acute lymphoblastic leukemia (ALL)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acute lymphoblastic leukemia (ALL) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview ...Read More
Apr 2016 $4950.00
"Age-related macular degeneration (AMD)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Age-related macular degeneration (AMD) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overv ...Read More
Apr 2016 $4950.00
"Alzheimer’s disease (AD)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the d ...Read More
Apr 2016 $4950.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

Published By :  Global Markets Direct

For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z